AACP
VNDA icon

Advantage Alpha Capital Partners’s Vanda Pharmaceuticals VNDA Stock Holding History

Advantage Alpha Capital Partners’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-339,333
Closed -$1.43M – 163
2023
Q4 		$1.43M Buy
+339,333
New +$1.37M 0.27% 90

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Advantage Alpha Capital Partners's VNDA Position: Q1 2024 in Review

Advantage Alpha Capital Partners sold out of Vanda Pharmaceuticals (VNDA) in Q1 2024, closing a stake of 339,333 shares — an estimated $1.43M sold.

Advantage Alpha Capital Partners first reported a position in VNDA in Q4 2023 and held it in 1 quarter. The position peaked at $1.43M in Q4 2023. 144 funds tracked by Wall St. Rank hold VNDA as of Q1 2024.

  • Advantage Alpha Capital Partners reported no remaining Vanda Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Advantage Alpha Capital Partners sold 339,333 Vanda Pharmaceuticals shares in Q1 2024, an estimated $1.43M.
  • Advantage Alpha Capital Partners first reported a position in Vanda Pharmaceuticals in Q4 2023 and held it in 1 quarter.
  • Advantage Alpha Capital Partners's Vanda Pharmaceuticals position peaked at $1.43M in Q4 2023.
  • 144 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2024.

Based on Advantage Alpha Capital Partners's 13F filing for Q1 2024, filed 13 May 2024.